Is NeoGenomics, Inc. overvalued or undervalued?

As of 25 February 2022, the valuation grade for NeoGenomics, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, given its negative valuation ratios, including a Price to Book Value of 1.07, an EV to EBIT of -14.14, and an EV to EBITDA of -131.00. Comparatively, peers such as The Ensign Group, Inc. have a P/E ratio of 32.46 and an EV to EBITDA of 21.10, showcasing a stark contrast in valuation metrics.
Additionally, NeoGenomics has underperformed significantly relative to the S&P 500, with a year-to-date return of -47.69% compared to the index's 12.22%. This underperformance, coupled with the company's negative returns over multiple periods, further reinforces the assessment that NeoGenomics is overvalued in its current state.